文献リスト

1) Yamaguchi T HT, Kiuchi H. Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic Stroke. Cerebrovasc Diseases. 1993; 3: 269-72

2) Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992; 42: 976-82

3) del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992; 32: 78-86

4) Ringelstein EB, Biniek R, Weiller C, et al. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology. 1992; 42: 289-98

5) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995; 333: 1581-7

6) Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0. 6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006; 37: 1810-5

7) Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007; 369: 275-82

8) Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283: 1145-50

9) Hill MD, Buchan AM. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci. 2001; 28: 232-8

10) 田辺三菱製薬株式会社・協和発酵株式会社. アルテプラーゼ注(虚血性脳血管障害急性期)使用成績調査の中間集計-第4回-. 2008年9月

11) Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282: 2019-26

12) Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000; 31: 811-6

13) Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274: 1017-25

14) Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352: 1245-51

15) Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363: 768-74

16) Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008; 359: 1317-29

17) Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4. 5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008; 372: 1303-9

18) Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3- to 4.5-hours after acute ischemic stroke. A Metaanalysis. Stroke. 2009; 40: 2438-41

19) Del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40: 2945-8

20) Whiteley W, Lindley R, Wardlaw J, et al. Third international stroke trial. Int J Stroke. 2006; 1: 172-6

21) Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004; 35: 904-11

22) The Interventional Management of Stroke (IMS) II Study. Stroke. 2007; 38: 2127-35

23) Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008; 39: 1205-12

24) 日本脳卒中学会医療向上・社会保険委員会 rt-PA(アルテプラーゼ)静注療法指針部会: rt-PA(アルテプラーゼ)静注療法的性治療指針. 脳卒中. 2005; 27: 327-53

25) Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004; 351: 2170-8

26) Molina CA, Ribo M, Rubiera M, et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke. 2006; 37: 425-9

27) Saqqur M, Tsivgoulis G, Molina CA, et al. Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO). Int J Stroke. 2008; 3: 66-72

28) Barreto AD, Sharma VK, Lao AY, et al. Safety and dose-escalation study design of Transcranial Ultrasound in Clinical SONolysis for acute ischemic stroke: the TUCSON Trial. Int J Stroke. 2009; 4: 42-8

29) Fessler AJ, Alberts MJ. Stroke treatment with tissue plasminogen activator in the setting of aortic dissection. Neurology. 2000; 54: 1010

30) Gerber O, Heyer EJ, Vieux U. Painless dissections of the aorta presenting as acute neurologic syndromes. Stroke. 1986; 17: 644-7

31) Kimura K, Hashimoto Y, Dosaka A, et al. [A case report of thoracic aortic and common carotid artery dissecting aneurysm diagnosed by duplex ultrasound examination]. Rinsho Shinkeigaku. 1996; 36: 348-51

32) Kimura K, Iguchi Y, Shibazaki K, et al. Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke. Stroke. 2008; 39: 2388-91

33) Kimura K, Iguchi Y, Yamashita S, et al. Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci. 2008; 267: 57-61

34) Kimura K, Iguchi Y, Shibazaki K, et al. M1 Susceptibility Vessel Sign on T2＊ as a Strong Predictor for No Early Recanalization After IV-t-PA in Acute Ischemic Stroke. Stroke. 2009; 40: 3130-2

35) Kimura K, Iguchi Y, Shibazaki K, et al. Recanalization of the MCA should play an important role in dramatic recovery after t-PA therapy in patients with ICA occlusion. J Neurol Sci. 2009; 285: 130-3

36) Kimura K, Iguchi Y, Shibazaki K, et al. Recanalization between 1 and 24 hours after t-PA therapy is a strong predictor of cerebral hemorrhage in acute ischemic stroke patients. J Neurol Sci. 2008; 270: 48-52

37) Kimura K, Iguchi Y, Shibazaki K, et al. Hemorrhagic transformation of ischemic brain tissue after t-PA thrombolysis as detected by MRI may be asymptomatic, but impair neurological recovery. J Neurol Sci. 2008; 272: 136-42

38) Kimura K, Iguchi Y, Shibazaki K, et al. The presence of a right-to-left shunt is associated with dramatic improvement after thrombolytic therapy in patients with acute ischemic stroke. Stroke. 2009; 40: 303-5

39) Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006; 60: 508-17

40) Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008; 7: 299-309

41) Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009; 8: 141-50

42) Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006; 63: 1057-62

43) Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008; 39: 3268-76

44) Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006; 354: 588-600

45) Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007; 357: 562-71

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp